TY - JOUR
T1 - Angioedema from recombinant TPA administration
T2 - Case report and pathophysiology review
AU - Foster-Goldman, Alison
AU - McCarthy, Danielle
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Angioedema is an uncommon, yet morbid, adverse reaction to recombinant tissue plasminogen activator (rtPA) administration for ischemic stroke. Orolingual edema may preclude completion of rtPA therapy and cause potential airway compromise. Few case reports and case series have examined the incidence of angioedema and anaphylaxis related to this common stroke therapy. We report a case of orolingual edema and bleeding in a patient who received rtPA for acute ischemic stroke who was concurrently on an angiotension-converting enzyme inhibitor and discuss the pathophysiology of this reaction.
AB - Angioedema is an uncommon, yet morbid, adverse reaction to recombinant tissue plasminogen activator (rtPA) administration for ischemic stroke. Orolingual edema may preclude completion of rtPA therapy and cause potential airway compromise. Few case reports and case series have examined the incidence of angioedema and anaphylaxis related to this common stroke therapy. We report a case of orolingual edema and bleeding in a patient who received rtPA for acute ischemic stroke who was concurrently on an angiotension-converting enzyme inhibitor and discuss the pathophysiology of this reaction.
KW - ACE-inhibitors and rt-PAinteraction
KW - Angioedema
KW - Orolingual edema
KW - Rt-PA adverse reaction
UR - http://www.scopus.com/inward/record.url?scp=84904375718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904375718&partnerID=8YFLogxK
U2 - 10.1097/MJT.0b013e3182799083
DO - 10.1097/MJT.0b013e3182799083
M3 - Article
C2 - 24247033
AN - SCOPUS:84904375718
VL - 20
SP - 691
EP - 693
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
SN - 1075-2765
IS - 6
ER -